WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1998013001) INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1998/013001    International Application No.:    PCT/US1997/017475
Publication Date: 02.04.1998 International Filing Date: 29.09.1997
Chapter 2 Demand Filed:    23.04.1998    
IPC:
A61K 9/00 (2006.01), A61K 31/4402 (2006.01), A61K 47/20 (2006.01)
Applicants: NASTECH PHARMACEUTICAL COMPANY, INC. [US/US]; 45 Davids Drive, Hauppauge, NY 11778 (US)
Inventors: BEHL, Charanjit, R.; (US).
DEMEIRELES, Jorge, C.; (US).
PIMPLASKAR, Harish, K.; (US).
ROMEO, Vincent, D.; (US).
SILENO, Anthony, P.; (US).
XIA, Wei, J.; (US)
Agent: BODNER, Gerald, T.; Hoffmann & Baron, LLP, 350 Jericho Turnpike, Jericho, NY 11753 (US)
Priority Data:
60/026,811 27.09.1996 US
Title (EN) INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME
(FR) FORMULATIONS INTRANASALES POUR FAVORISER LE SOMMEIL ET LEUR PROCEDE D'UTILISATION
Abstract: front page image
(EN)Intranasal dosage units for promoting sleep in a mammal are disclosed. The dosage units are in the form of an aqueous buffered solution having a pH greater than 7.0, a sleep-promoting amount of Doxylamine, and an effective amount of an anionic surfactant. The anionic sufactant amount is an amount effective to provide a peak plasma concentration of Doxylamine to be reached within 30 minutes of administering the dosage unit to the nasal mucosa of a mammal. The dosage units are particularly suitable for administration to humans.
(FR)L'invention concerne des unités posologiques intranasales destinées à favoriser le sommeil chez un mammifère. Les unités posologies ont la forme d'une solution aqueuse tamponée au pH supérieur à 7.0, possédant une dose de Doxylamine favorisant le sommeil, et une dose efficace de surfactant anionique. La dose de surfactant anionique est une dose efficace pour atteindre une concentration maximum de Doxylamine dans le plasma au cours des trente minutes qui suivent l'administration de l'unité posologique dans la muqueuse nasale d'un mammifère. Les unités posologiques sont particulièrement adaptées à l'administration aux humains.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW.
African Regional Intellectual Property Organization (GH, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)